Soluble urokinase-type plasminogen activator receptor as a putative marker of male accessory gland inflammation

被引:10
|
作者
Autilio, C. [1 ]
Morelli, R. [1 ]
Milardi, D. [2 ]
Grande, G. [2 ]
Marana, R. [2 ]
Pontecorvi, A. [3 ]
Zuppi, C. [1 ]
Baroni, S. [1 ]
机构
[1] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Sch Med, Dept Diagnost & Lab Med, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Sch Med, Int Sci Inst Paul VI Res Human Fertil & Infertil, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Sch Med, Dept Endocrinol, I-00168 Rome, Italy
关键词
infection; inflammation; male accessory gland infection/inflammation; semen analysis; sperm quality parameters; subfertility; OXIDATIVE STRESS; SEMEN QUALITY; AUTOIMMUNE-RESPONSE; MALE-INFERTILITY; SEMINAL PLASMA; GROWTH-FACTOR; PROSTATITIS; ELASTASE; SUPAR; INFECTIONS;
D O I
10.1111/andr.12084
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
The association between male accessory gland infection/inflammation (MAGI) and infertility is well-known in clinical practice. Standard semen analysis, leukocytospermia, and microbiological tests are often not enough accurate for a diagnosis. A large amount of biochemical parameters in seminal plasma have been suggested as inflammation markers, however, there is not yet a sensitive and specific biomarker that accurately identifies MAGI. We investigated the presence of soluble urokinase-type plasminogen activator receptor (suPAR), known marker of systemic inflammation, in the seminal plasma to evaluate its possible involvement in urogenital tract inflammation. On the basis of andrological evaluation, including spermiogram and ultrasound findings, we selected 76 patients with MAGI and 30 healthy men as control group. Patients were classified according to the results of the semen culture in group A (n = 28) presenting a bacterial MAGI and group B (n = 48) with abacterial MAGI. C-reactive protein (CRP), total protein (TP), procalcitonin (PCT), leukocytes peroxidase (LP), and suPAR concentrations were assayed on seminal plasma. Spermiogram parameters were significantly lower in the patients with MAGI than in controls. CRP, TP, PCT, and LP did not differ in MAGI vs. controls. suPAR was detectable in all semen samples; it was significantly increased in A and B groups (86.6 +/- 30.7 ng/mL vs. 39.7 +/- 17.2 ng/mL) with an inverse correlation with sperm parameters. We selected by receiver operating characteristic curve a suPAR cut-off value of 55.3 ng/mL as a diagnostic threshold for the diagnosis of MAGI. We report in this study the first evidence of suPAR presence in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of MAGI.
引用
收藏
页码:1054 / 1061
页数:8
相关论文
共 50 条
  • [31] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128
  • [32] Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels in male patients with acute exacerbation of schizophrenia
    Genc, A.
    Kalelioglu, T.
    Karamustafalioglu, N.
    Tasdemir, A.
    Genc, E. Sena
    Akkus, M.
    Emul, M. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S232 - S233
  • [33] Significance of Soluble Urokinase-type Plasminogen Activator Receptor in Patients with Coronary Heart Disease
    Zheng, Zhenda
    Cheng, Cailian
    Liu, Dinghui
    Song, Zhiming
    Chen, Lin
    Qian, Xiaoxian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (16) : C144 - C144
  • [34] Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients
    Donadello, Katia
    Scolletta, Sabino
    Taccone, Fabio Silvio
    Covajes, Cecilia
    Santonocito, Cristina
    Cortes, Diego Orbegozo
    Grazulyte, Daiva
    Gottin, Leonardo
    Vincent, Jean-Louis
    JOURNAL OF CRITICAL CARE, 2014, 29 (01) : 144 - 149
  • [35] Effect of Dapagliflozin on Soluble Urokinase-Type Plasminogen Activator Receptor in Type 2 Diabetes with Albuminuria
    Curovic, Viktor Rotbain
    Eickhoff, Mie K.
    Houlind, Morten B.
    Frimodt-Moller, Marie
    Hansen, Tine
    Eugen-Olsen, Jesper
    Rossing, Peter
    Persson, Frederik
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 275 - 275
  • [36] Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker of Treatment Response in Childhood Tuberculosis
    Olivianto, Ery
    Sudarwati, Sri
    Nataprawira, Heda Melinda
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2019, 8 (03) : 262 - 266
  • [37] Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson's disease
    Witek, N.
    Joyce, J.
    Hawkins, J.
    Liu, Y.
    Ouyang, B.
    Patel, R.
    Borgia, J.
    Reiser, J.
    Hall, D.
    MOVEMENT DISORDERS, 2021, 36 : S460 - S460
  • [38] Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism
    Joyce, Jessica
    Cabanas, Noel
    Pisharody, Rohan
    Ouyang, Bichun
    Patel, Roshni
    Reiser, Jochen
    Hall, Deborah A.
    Witek, Natalie
    PARKINSONISM & RELATED DISORDERS, 2022, 101 : 39 - 42
  • [39] Urokinase-type plasminogen activator: a new target for male contraception
    Qin, Ying
    Han, Yan
    Xiong, Cheng-Liang
    Li, Hong-Gang
    Hu, Lian
    Zhang, Ling
    ASIAN JOURNAL OF ANDROLOGY, 2015, 17 (02) : 269 - 273
  • [40] Serum Soluble Urokinase-type Plasminogen Activator Receptor is Associated With the Prevalence of Atrial Fibrillation
    Miyamura, Masatoshi
    Ichihara, Noboru
    Yamauchi, Yohei
    Fujimura, Yuki
    Maeda, Daichi
    Fujisaka, Tomohiro
    Fujita, Shu-ichi
    Morita, Hideaki
    Takeda, Yoshihiro
    Ito, Takahide
    Sohmiya, Koichi
    Hoshiga, Masaaki
    Ishizaka, Nobukazu
    CIRCULATION, 2017, 136